Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol 3350 and electrolytes (PEG 3350 and electrolytes) is an osmotic laxative and bowel-cleansing preparation. It is formulated as a powder for oral solution or as a pre-mixed oral solution, containing polyethylene glycol 3350 as the active osmotic agent combined with essential electrolytes (such as sodium sulfate, sodium bicarbonate, sodium chloride, and potassium chloride) to maintain fluid and electrolyte balance during bowel evacuation. PEG 3350 works by retaining water in the intestinal lumen through osmotic action, which softens the stool, increases stool volume, and promotes peristalsis. This combination is widely indicated for whole bowel irrigation in preparation for colonoscopy or other gastrointestinal procedures, as well as for the treatment of chronic constipation and fecal impaction, particularly in pediatric populations. Key developers of formulations of this drug include Sunflower Pharmaceutical Group and Guangzhou Kanghe Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 3350 and electrolytes (Braintree Laboratories).